Sciwind Biosciences Completes $70 Million Series C Financing And Expands Leadership Team To Advance Metabolic Disease Pipeline
Sciwind Biosciences Completes $70 Million Series C Financing And Expands Leadership Team To Advance Metabolic Disease Pipeline
10/12/21, 11:00 AM
Location
hangzhouMoney raised
$70 million
Round Type
series c
Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced the closing of an $70 million Series C financing. The financing round was co-led by IDG Capital, Loyal Valley Capital and LYFE Capital. Sciwind plans to use the proceeds to advance clinical development of its proprietary GLP-1 receptor agonism candidates and anticipates the following development milestones from the three lead programs:
Company Info
Location
hangzhou, zhejiang, china
Additional Info
Sciwind Biosciences is a clinical stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic diseases. Its product pipeline consists of potentially first-in-class and best-in-class drug candidates. Sciwind also developed multiple proprietary technologies, including oral peptide and inhaled protein therapeutics delivery platforms and has identified multiple drug candidates based on these core platform technologies. For more information, visit www.sciwindbio.com.